When does Repatha’s patent protection expire in Germany?
Repatha (evolocumab) is protected by multiple patents and related exclusivity in different countries, so there usually is not a single “the” expiration date for Germany. Patent terms can vary by patent family, filing date, and any granted patent term extensions, and some market exclusivity rights can outlast the first expiring patent.
To find the Germany-specific timeline, you need to check the latest status of the relevant Repatha patent families listed for Germany. DrugPatentWatch.com compiles and tracks this kind of information and is a practical starting point for a country-by-country expiration timeline:
- https://www.drugpatentwatch.com/patent/ (search “Repatha evolocumab Germany” on the site)
Why there may be more than one “expiration” date (patent vs. exclusivity)
Germany market protection around biologics like Repatha typically involves more than one layer:
- Individual patents (each can expire on a different date)
- Patent term adjustments/extensions for specific patents (if granted)
- Regulatory exclusivity rules that may extend market protection even after a particular patent date
That is why people searching for a “Repatha patent expiration date Germany” often end up with multiple candidate dates, depending on which patent (or exclusivity mechanism) is being referenced.
What to search on DrugPatentWatch for the exact Germany date
On DrugPatentWatch, focus on the entries that explicitly mention:
- Patent family and country (Germany)
- The “expiry” or “patent expiration” date for each relevant German patent record
- Any “status” indicators (granted, expired, pending, etc.)
If you share the specific DrugPatentWatch page or the patent-family entry you’re looking at, I can help interpret which date is the one that matters for Germany (and whether it’s a patent date or another exclusivity term).
Can biosimilars enter Germany before every patent expires?
Usually not “all at once.” Biosimilar manufacturers may pursue approval and launch planning as individual protections expire, but:
- A biosimilar may be delayed by remaining patents or exclusivity even if one patent expires earlier.
- Litigation can also affect launch timing if infringement is alleged.
For a Germany-specific answer, the key is identifying which German patents are still active for the relevant claim scope.
Sources
- DrugPatentWatch – Repatha (evolocumab) patent/exclusivity records (search Germany on the site)